Bioventus is a medical devices business based in the US. Bioventus shares (BVS) are listed on the NASDAQ and all prices are listed in US Dollars. Bioventus employs 1,160 staff and has a trailing 12-month revenue of around $516.7 million.
Finder Award
eToro
Finder Award
SoFi Invest
| Latest market close | $2.06 |
|---|---|
| 52-week range | $1.65 - $15.10 |
| 50-day moving average | $2.47 |
| 200-day moving average | $7.01 |
| Wall St. target price | $6.50 |
| PE ratio | 11.4444 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.18 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.06 from 2023-01-24
| 1 week (2023-01-19) | -7.21% |
|---|---|
| 1 month (2022-12-23) | -18.90% |
| 3 months (2022-10-26) | -72.24% |
| 6 months (2022-07-26) | -74.38% |
| 1 year (2022-01-26) | -83.83% |
|---|---|
| 2 years (2021-01-22) | N/A |
| 3 years (2020-01-22) | N/A |
| 5 years (2018-01-22) | N/A |
Valuing Bioventus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioventus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bioventus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Bioventus shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Bioventus's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.
Bioventus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1421. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bioventus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Bioventus's PEG ratio in relation to those of similar companies.
Bioventus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $25.6 million.
The EBITDA is a measure of a Bioventus's overall financial performance and is widely used to measure a its profitability.
To put Bioventus's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $516.7 million |
|---|---|
| Gross profit TTM | $302.7 million |
| Return on assets TTM | -1.07% |
| Return on equity TTM | -55.9% |
| Profit margin | -24.61% |
| Book value | $5.56 |
| Market capitalisation | $127.6 million |
TTM: trailing 12 months
We're not expecting Bioventus to pay a dividend over the next 12 months.
You may also wish to consider:
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
We explore some of the best brokerage accounts for international stock trading. Here’s what you need to know.
